drugset / Trial / NCT00746837

AZD5672 Absolute Bioavailability Study

NCT00746837

Phase 1 Completed 26 enrolled AstraZeneca
RandomizedSingle-groupDouble-blindBasic science

Summary

The purpose of the study is to estimate the absolute bioavailability at steady state of 2 doses of AZD5672 (50 mg and 150 mg administered orally once daily)

Timeline

Start
2008-08
Primary completion
2009-01
Completion
2009-01

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD5672 Small molecule 7 mg Intravenous
Subject AZD5672 Small molecule 50 mg Intravenous
Subject AZD5672 Small molecule 150 mg Intravenous

Indications

No indication recorded.